securing up to €1 million from ACT Venture Partners.
Meddenovo Drug Design is pleased to announce they has completed the first closing of their pre-seed investment round, securing up to €1 million from ACT Venture Partners. This initial funding will accelerate the development of their AI-powered platforms for innovative therapeutic solutions. Co-founded by Dr. Ilke Ugur Marion and Dr. Antoine Marion, Meddenovo leverages advanced molecular modeling and the unique properties of cyclic peptides to revolutionize drug design. This investment will enhance their AI-driven capabilities, transition to a SaaS model, and expand their partnerships and customer base, positioning them to make a significant impact in the pharmaceutical industry by streamlining the development of effective therapies.
©Meddenovo